Abstract: Topical formulations and methods use are described herein for relieving symptoms created by herpes simplex, mouth ulcers, and yeast infections. The formulations comprise effective amounts of d-limonene.

Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

Abstract: A carotenoid substance called zeaxanthin, when ingested orally at suitable dosages such as 30 to 100 mg/day for a span of 1 to 2 weeks, can provide effective protection against sunburns, and can give skin a darker tint that emulates a healthy suntan. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce: (i) a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan; (ii) a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure; and, (iii) an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. Oral ingestion of dosages of zeaxanthin after a noticeable darkening of the skin has been achieved further enhances a tanned appearance and/or protects against sun damage.

Abstract: The present invention is related to solid pharmaceutical preparations containing diatomaceous earth (diatomite) or a natural mineral mixture containing diatomaceous earth as filler besides the active ingredient and optional other auxiliary agents. A further object of the invention is a method for manufacturing such pharmaceutical preparations.

Abstract: Disclosed is a microcapsule composition for inhibiting an ethylene response in plants, which comprises a plurality of microcapsules, each including an agent for blocking an ethylene binding site in plants in an oil droplet, and a coating encapsulating the oil droplet and the agent for blocking the ethylene binding site in plants. A method for preparing microcapsules of an agent for blocking the ethylene binding site in plants, and a method for inhibiting an ethylene response in plants are also disclosed.

Abstract: The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3 protein of Bluetongue). The present invention further relates, inter alia, to compounds which have been shown to possess antiviral activity, in particular, inhibiting the M2 proton channel of influenza viruses.

Abstract: Insecticidal compositions have at least one active agent and at least one insecticide. The active agent can include perilla oil, a component found in perilla oil, or a perillaldehyde or carvone analog. The insecticide can include a pyrethrum, pyrethrin, pyrethroid, neonicotinoid, chlofenapyr, ethiprole, sulfoxoflor, carbamate, organophosphate, or organochlorine. Methods for controlling insects include contacting an insect with an effective amount of a composition described in this specification. Modified plants that produce an active agent can be contacted with an insecticide.

Abstract: Disclosed is an anti-tumor plant-medicament sustained-release tablet of elemene which comprises an elemene as an active component and is prepared by formulation of the elemene, a sustained-release agent, a bulking agent, a disintegrating agent, a binder and a lubricant, each component above-mentioned being in the following weight composition: the elemene 10%-15%, the sustained-release agent 3%-15%, the bulking agent 45%-70%, the disintegrating agent 3%-8%, the binder 1%-10%, and the lubricant 1%-8%. The sustained-release tablet of elemene provided in the invention has properties of expansion and adhesion, which in turn enables extending the retention time of the drug on upper and middle sections of the gastrointestinal tract. Therefore, the tablet may be taken b.i.d.×3, in order to attain reduction in fluctuation of the plasma concentration, maintain effective plasma concentration for a longer period, and reduce the irritation on the gastrointestinal tract.

Abstract: Skin compositions comprising, hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and related method for protecting, healing and/or soothing the skin comprising: applying an effective amount of a cosmetic preparation selected from the group consisting of hand cream, foot cream, body cream, lip cream, lip gloss, lip stick, gel, balm and lotion to the skin surface; wherein said cosmetic preparation includes a skin composition made of hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and said effective amount is enough to protect, heal and/or soothe the skin surface.

Abstract: Linalool and other materials which are skin penetrating vasodilators or which can be made to have such properties are applied, either by themselves or in skin treatment compositions, to the skin of the head and especially the back of the neck to prevent or alleviate the effects of migraine headaches or applied to sore muscles or ligaments to aid in minimizing the soreness, or are applied to wrinkled and/or old looking skin on the face, neck, torso, or extremities, other than on the hands, to minimize wrinkles and/or improve the skin's appearance and/or are applied to the head to grow hair on the head or prevent hair loss.

Abstract: The present invention relates to a method of preparing for an oil suspension of carotenoid with low viscosity and high fluidity and use thereof. The method comprises the following steps: mixing carotenoid crystals with tetrahydrofuran, heating the mixture to reflux temperature 50˜70°C. under stirring to dissolve the crystal, filtering and condensing to obtain the concentrate; mixing the concentrate with ketone solvent, heating the mixture to reflux temperature 60-80? to dissolve the concentrate, filtering, condensing, adding absolute alcohol, crystallizing under stirring at room temperature, filtering and drying in vacuum to obtain carotenoid crystals; mixing carotenoids crystals after granded with plant oil or grinding carotenoid crystals with plant oils and then adding plant oil, to obtain the oil suspension of carotenoid with low viscosity and high fluidity. While the content of carotenoid is 10.0˜45.0 wt.

Abstract: An oral microemulsion of elemene is disclosed. The microemulsion is made of elemene, surfactant, cosurfactant and water or buffer solutions with pH 5˜8. Said surfactant is selected form tweens, polyoxyethylene castor oils, polyethylene glycol stearates and mixture thereof. Said cosurfactant is selected from ethanol, 1,3-propanediol, glycerol and mixture thereof. The concentration of elemene in the microemulsion is 1˜5 g/100 ml. The ratio of elemene, surfactant and cosurfactant is 1˜5(weight):1˜40(weight):1˜40(volume), wherein the unit of weight/volume is g/ml.

Abstract: The present invention relates to a base formulation for cosmetic products, characterized in that it comprises, in percentage by weight of the formulation and according to the INCI nomenclature: a) from 0.2 to 10% of at least one hydroxylated ester; b) from 0.5 to 70% of a mixture of at least one mineral oil and at least one copolymer derived from alkenes; c) from 0.5 to 90% of at least one hydrogenated polymer; d) from 0.5 to 35% of a mixture of water and at least one glyceryl glucoside. Likewise, an object of this invention is a cosmetic product characterized in that it comprises the aforementioned base formulation, as well as the preparation procedure of the same.

Abstract: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.

Abstract: The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by administrating PKC agonist into an animal model. Therefore, the composition of the present invention comprising PKC agonist as an active ingredient can be effectively used for the prevention and treatment of absence seizure and for the production of health improving functional food.

Abstract: The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in canines by administering to the canines an ophthalmic malady ameliorating amount of one or more carotenes. Generally, the carotenes are administered to the canines in amounts of from about 0.1 to about 5000 mg or in amounts of from about 0.1 to about 500 mg per day to ameliorate maladies such as impaired vision, cataracts, cloudy eye, retinal degeneration, eye injury caused by radiation, reducing or preventing a decline of social interaction, promoting overall health and wellness, improving the quality of life, and extending the prime for canines.

Abstract: The subject application relates to methods of treatment of peripheral vascular disease (PVD) as well as ischemic osteonecrosis, peritoneal ischemia, chronic ocular disease, macular degeneration, or diabetic retinopathy, comprising administering a therapeutically effective amount of a trans carotenoid. The invention also relates to the use of such carotenoids as pretreatments for mammals at risk of an ischemic event.

Abstract: A process for the hydrogenation of a mixture of caryophyllenes by contact with hydrogen in the presence of a supported catalyst. The resulting products are useful for the application to skin.

Abstract: The present invention provides a process for preparing an aqueous dispersion containing a high concentration of nano/submicron, hydrophobic, functional compounds. The process is carried out by using a complex stabilizer having an HLB value of about 10 to about 17, comprising lecithin and at least one non-phospholipid selected from polysorbate, sucrose ester, and polyglycerol fatty acid ester; selecting a specific weight ratio of the hydrophobic functional compounds and the stabilizer; and using homogenization technique, media milling technique, and/or centrifugal technique. The aqueous dispersion containing a high concentration of nano/submicron, hydrophobic, functional compound produced by the process of the invention has stable dispersibility and improved bioavailability, and can be applied to the fields of foods and pharmaceuticals.

Abstract: The present invention is directed to carotenoid-containing compositions and methods for improving bone or respiratory health in a subject comprising administering to the subject a combination of lycopene, beta-carotene, and beta-cryptoxanthin.

Abstract: An emulsifiable concentrate for emulsified phytosanitary composition, including more than 90% by weight of at least one mixture of hydrocarbons having a distillation cut greater than 250° C., less than 20% by weight of n-paraffins and less than 1% aromatics, and from 1 to 4% by weight of a mixture of at least two surfactants TA1 and TA2, such that TA2 is more hydrophobic than TA1, the HLB of the mixture of which varies from 6 to 10.

Abstract: A beverage for minimizing or reducing jet lag symptoms preferably includes vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin D, zinc, calcium, iodine, magnesium, manganese, ginseng, ginkgo biloba, grape seed extract, Echinacea extract and water. A method for minimizing or reducing jet lag symptoms including ingestion of the beverage by a traveler, one hour prior to a flight, and/or during the flight, and/or after a flight.

Abstract: The invention relates to therapeutic methods comprising use of oligomeric and polymeric forms of the monoterpene compounds alloocimene, limonene, alpha-pinene, beta-pinene, geranyl acetate, alpha-phellandrene, gamma-terpinene, 3-carene and 2-carene. More particularly, the invention relates to methods of treating degenerative neurological conditions, and treating skin disorders.

Abstract: There is provided a composition comprising an oil medium, wherein particles are suspended in said oil medium, wherein said particles comprise cyclopropene and molecular encapsulating agent, and wherein said particles have median size, as measured by the largest dimension, of 50 micrometer or less. Also provided are a method of making such a composition and a method of treating plants by contact with such a composition.

Abstract: A pet food composition having at least two carotenoids. The carotenoids can include a keto-carotenoid and at least one non-keto-carotenoid. The keto-carotenoid can include astaxanthin. The keto-carotenoid can include astaxanthin ester. The non-keto-carotenoid can include beta-carotene and/or lutein.

Abstract: cis-Jasmone has been discovered to be useful as a semiochemical that changes the behavior of insects and/or the physiology of plants. It has direct signalling roles with plant-feeding aphids, in attraction of aphid predators and parasitoids, and may act as an airborne signal inducing production of volatile plant semiochemicals, including the monoterpene (E)-?-ocimene, that stimulate foraging by parasitoids. It is an extremely benign compound having, to human beings, a pleasant aroma and gives a long-lasting effect after removal of the stimulus.

Abstract: Novel plant essential oil-based antimicrobial filming compositions that are useful in protecting, repairing and strengthening the natural slime coat found on fish are disclosed, which compositions are comprised of a mixture of plant essential oils having antimicrobial properties, filming agents, and surfactants.

Abstract: This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired.

Abstract: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials.

Abstract: Shelf-stable fermented dairy products and methods of making the shelf-stable fermented dairy products are provided. The shelf-stable fermented dairy products can be shelf-stable with improved taste, viscosity and texture profiles. In a general embodiment, the present disclosure provides a shelf-stable fermented dairy product including a shelf-stable fermented dairy component, a stabilizer, and a puree composition. The shelf-stable fermented dairy component can be, for example, yogurt, sour cream, buttermilk or a combination thereof.

Abstract: In accordance with one aspect of the invention, a method is provided in which post-surgical adhesions at a surgical site in a patient are inhibited. The method includes topically applying a liquid composition comprising a hydrophobic species, which has a melting point above normal body temperature, to tissue at the surgical site in an amount effective to inhibit the formation of adhesions during healing.

Abstract: The present invention provides compounds and compositions for attracting or repelling sap-sucking insects, such as whitefly, as well as methods for using such compositions.

Abstract: The present invention relates to a stabilizer comprising starch that comprises at least one ester group corresponding to the formula (I) wherein M+ is an alkali metal, M2+ is an alkaline earth metal, R is an alkylene radical and R? is an alkyl or alkenyl group having 5 to 18 carbon atoms and less than 0.1% by weight of free alkyldicarboxylic acid compounds or alkenyldicarboxylic acid compounds or mixtures thereof, based on the total weight of the starch, a method for the production thereof, and also to the use thereof for increasing the stability of a substance that is to be stabilized.

Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).

Abstract: The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE2 in a mammalian subject comprising administering to said subject the aforementioned therapeutic composition.

Abstract: The present invention relates to a process of a dispersion of an active substance or composition in a aqueous phase which comprises dispersing in an aqueous phase a solution of such substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing the mixture and separating the dispersion from the gaseous solvent.

Abstract: An edible plant-extract-based insecticidal composition comprises d-limonene, a non-toxic hydrophilic solvent, and an amount of a polyethoxylated castor oil sufficient to solubilize the d-limonene in the hydrophilic solvent. The castor oil is both an emulsifier and an active ingredient having insecticidal efficacy. The insecticidal composition is non-toxic to humans and household animals.

Abstract: Stabilized liquid agrochemical compositions are provided which comprise flowable non-aqueous dispersion concentrates comprising a continuous substantially water-miscible liquid phase, a dispersed water-immiscible liquid phase, and a colloidal solid. In one embodiment, the dispersed phase comprises at least one water-sensitive agrochemically active ingredient and the colloidal solid is disposed at the interface between the dispersed phase and the continuous phase. In another embodiment, the water-sensitive agrochemically active ingredient is a solid but is dissolved in an oily liquid present in the dispersed phase, or is a solid and is dispersed within the dispersed phase, or is a solid complex of an agrochemical with a molecular complexing agent and is dispersed within the dispersed phase. The compositions of the invention can be used directly or with dilution to combat pests or as plant growth regulators.

Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.

Abstract: The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ?380, preferably of ?600, most preferably ?900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ?30% when pressed to tablets.

Abstract: The present invention relates to a ready-to-use stable suspension of partially amorphous carotenoid particles, a process for production thereof and also use thereof as additive to animal feeds, foods and food supplements and also cosmetic and pharmaceutical compositions.

Abstract: A carotenoid substance called zeaxanthin, when ingested orally at suitable dosages such as 30 to 100 mg/day for a span of 1 to 2 weeks, can provide effective protection against sunburns, and can give skin a darker tint that emulates a healthy suntan. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce: (i) a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan; (ii) a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure without any subsequent pain or discomfort, and without the subsequent peeling and flaking that characterizes sunburns; and, (iii) an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned.

Abstract: Provided is a pharmaceutical composition for permeabilizing fetal membranes including an active ingredient having a log K in the range of 2 to 4, where K is the octanol/water partition coefficient. The active ingredient may be, for example, bupivacaine, sodium lauryl sulfate or oleic acid. Further provided is a system for transfetal membrane transport. The system includes a probe unit adapted for insertion into a female reproductive tract and releasing a substance onto fetal membranes that permeabilizes the membranes. The system is also configured to apply ultrasound radiation to the fetal membranes to further increase the membrane permeability.

Abstract: Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-diethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and then mixing that solution with the other wall-forming reactant, such as the Lewis acid. Various adjuvants may be included with the core component to contribute additional characteristics, such as enhancement of a controlled release characteristic or improved mechanical stability.

Abstract: The present invention comprises compositions, methods and cell lines related to controlling insects. An embodiment of a composition comprises a plant essential oil and targets at least one receptor of insects chosen from tyramine receptor, Or83b olfactory receptor, and Or43a olfactory receptor, resulting in a change in the intracellular levels of cAMP, Ca2+, or both in the insects.

Abstract: The disclosure provides compositions and methods for reducing the mutation rate of a virus, such as an RNA virus or a DNA virus, in a cell infected with the virus by, in one aspect, contacting the cell with an effective amount of an iron chelator or an antioxidant. Also provided are compositions and methods for enhancing the efficacy of an agent or a therapy directed at a virus.

Abstract: The present invention relates to a stable emulsion, ready for use, of fat-soluble vitamins or carotenoids, a process for the preparation thereof, and the use thereof as addition to animal feeds, human foods and dietary supplements, and cosmetic and pharmaceutical compositions.

Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in a patient's blood vessels is provided. A chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive substance is administered at sites of the plaques. The chemical composition comprises one or more of d-limonene, propylene glycol, octanoic acid, 2-octane, glycerine, acetylsalicylic acid, acetic acid, omega-3 fatty acids, ethanol, methanol, ezetimibe, rosuvastatin, resveratrol, lactic acid, gluconic acid, chloroform, carbon disulfide, dichloromethane, toluene, lauryldimethyl hydroxysultaine, and any combination thereof. The chemical composition enables modification of plaques by altering their composition. The modification comprises partial dissolution, complete dissolution, or elimination of the plaques, and makes the plaques amenable to different forms of plaque treatment. The modified plaques are eliminated from the patient's body.

Abstract: [Problem to be Solved] The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. [Solution] A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.

Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to rejuvenate the skin and increase the protective layer against irradiation by ultraviolet radiation (UVR). More specifically it provides terpenes and terpenoids as ingredients that work as persistent UVR blockers. Terpenes and terpenoid compounds support the growth of skin, skin tissue and keratinocytes and additional UVR-blocking by reason of increased stratum corneum thickness and loricrin content. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 6 mg to about 600 mg per kilogram of body weight per day effective to stimulate growth of the skin layer and prevent damage from ultraviolet radiation (UVR).